Weaned, via Whitaker

What do you do when you know your funding will soon run out?


Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In 2006, the Whitaker Foundation decided its work was done. The philanthropic organization was formed by U.A. and Helen Whitaker with the goal of creating a worldwide field of biomedical engineering. Once it determined it had achieved its "primary objective," it shut down.

The year before, 31 biomedical researchers received Whitaker grants, some close to $100,000. Trouble was, the money was guaranteed to disappear - and soon. Here, some present their advice on how to handle funding you know will run out.

Plan ahead.

It's obvious advice, but bears a mention. The minute Edward Brown at the University of Rochester received $93,550 from the Whitaker Foundation to pursue research on imaging angiogenesis and vascular function in tumors, he started looking for his next grant. "Certainly, you're looking for funding within the next year," he said. "Fortunately, that worked." Before his Whitaker grant was up, Brown had obtained a five-year grant ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development